ArticleOncoimmunology
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04212377 (An Exploratory Study), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Exploratory Study: Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Efficacy of Using Dendritic Cells in the Treatment of Prostate Cancer: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial.Journal of translational medicine · 2025Trial
- Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.Nature communications · 2024Trial
- Immunological responses to adjuvant vaccination with combined CD1cOncoimmunology · 2022Trial
- A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.Cancer immunology, immunotherapy : CII · 2020Trial
- Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.Cancer immunology, immunotherapy : CII · 2020Trial
- Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.Journal of hematology & oncology · 2017Trial
- Overcoming Resistance Mechanisms to Melanoma Immunotherapy.American journal of clinical dermatology · 2025Review
- Dendritic Cells in Cancer Immunology and Immunotherapy.Cancers · 2024Review
- Dendritic cell subsets and implications for cancer immunotherapy.Frontiers in immunology · 2024Review
- Review
- Review
- cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.Cancer immunology research · 2022Article
- Exosome application in tumorigenesis: diagnosis and treatment of melanoma.Medical oncology (Northwood, London, England) · 2022Review
- The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy.Frontiers in oncology · 2022Review
- Antigen transfer and its effect on vaccine-induced immune amplification and tolerance.Theranostics · 2022Review
- Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect.International journal of molecular sciences · 2021Review
- mRNA therapeutics in cancer immunotherapy.Molecular cancer · 2021Review
- The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy.Immunotherapy · 2020Review
- Antitumour dendritic cell vaccination in a priming and boosting approach.Nature reviews. Drug discovery · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma patients with regional metastatic disease are at high risk for recurrence and metastatic disease, despite radical lymph node dissection (RLND). We investigated the immunologic response and clinical outcome to adjuvant dendritic cell (DC) vaccination in melanoma patients with regional metastatic disease who underwent RLND with curative intent. In this retrospective study, 78 melanoma patients with regional lymph node metastasis who underwent RLND received autologous DCs loaded with gp100 and tyrosinase and were analyzed for functional tumor-specific T cell responses in skin-test infiltrating lymphocytes. The study shows that adjuvant DC vaccination in melanoma patients with regional lymph node metastasis is safe and induced functional tumor-specific T cell responses in 71% of the patients. The presence of functional tumor-specific T cells was correlated with a better 2-year overall survival (OS) rate. OS was significantly higher after adjuvant DC vaccination compared to 209 matched controls who underwent RLND without adjuvant DC vaccination, 63.6 mo vs. 31.0 mo (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.